Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria
Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria
Sponsor: NCHADS - Ministry of Health of Cambodia
Listed as NCT02389439, this PHASE2 trial focuses on Malaria, Falciparum and remains completed. Sponsored by NCHADS - Ministry of Health of Cambodia, it has been updated 9 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Unknown Status PHASE2
-
May 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NCHADS - Ministry of Health of Cambodia
- University of Oxford
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Battambang, Cambodia
- • Pailin, Cambodia
- • Pursat, Cambodia